专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08476310B2 Docetaxel formulations with lipoic acid 有权
标题翻译：多西他赛制剂与硫辛酸
公开(公告)号：US08476310B2
公开(公告)日：2013-07-02
申请号：US12721564
申请日：2010-03-11
申请人： Nagesh Palepu
发明人： Nagesh Palepu
IPC分类号： A61K31/337
CPC分类号： A61K31/337 , A61K9/0019 , A61K9/08 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Pharmaceutical formulations comprising docetaxel, solubilizer, and α-lipoic acid, wherein the formulation is substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol, acetic acid, benzyl alcohol, or ethanol. The α-lipoic acid, at certain concentrations, may impart stability and prevent degradation of docetaxel while the formulations are in storage. The formulations may be combined with a diluent, which comprises one or more hydrotropes such as tocopherol polyethylene glycol succinate and polyethylene glycol. The formulations combined with the diluent also exhibit stability after storage. Methods of administering docetaxel comprise preparing the formulation comprising docetaxel, solubilizer, and α-lipoic acid; mixing the formulation with a diluent; diluting the resulting formulation in saline, water for injection, or the like; and then injecting the formulations into patients in need thereof.
摘要翻译：包含多西紫杉醇，增溶剂和α-硫辛酸的药物制剂，其中所述制剂基本上不含聚山梨醇酯和聚乙氧基化蓖麻油。增溶剂可以包含糖福，乙酸，苄醇或乙醇。某些浓度的α-硫辛酸可以赋予稳定性并且在制剂储存时防止多西紫杉醇的降解。制剂可与稀释剂组合，稀释剂包含一种或多种水溶助长剂如生育酚聚乙二醇琥珀酸酯和聚乙二醇。与稀释剂组合的制剂在储存后也表现出稳定性。给予多西紫杉醇的方法包括制备包含多西他赛，增溶剂和α-硫辛酸的制剂; 将制剂与稀释剂混合; 将所得制剂稀释在盐水，注射用水等中; 然后将制剂注射到有需要的患者体内。

2. 发明申请

US20110046063A1 READY-TO-USE BIVALIRUDIN COMPOSITIONS 审中-公开
标题翻译：准备使用双维生素组合物
公开(公告)号：US20110046063A1
公开(公告)日：2011-02-24
申请号：US12856088
申请日：2010-08-13
申请人： Nagesh PALEPU , Rajeshwar MOTHERAM , Praful SHAH , Gopal KRISHNA
发明人： Nagesh PALEPU , Rajeshwar MOTHERAM , Praful SHAH , Gopal KRISHNA
IPC分类号： A61K38/10 , A61P9/00
CPC分类号： A61K38/58
摘要： Ready-to-use bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use bivalirudin compositions. The ready-to-use bivalirudin compositions comprise bivalirudin and one or more stabilizing agents. The one or more stabilizing agents may be buffering agents having a pKa of about 2.5 to about 6.5, pH-adjusting agents, polymers, preservatives, antioxidants, sugars or polyols, or a combination thereof. The ready-to-use bivalirudin compositions may also comprise [9-10]-cycloimido bivalirudin, [11-12]-cycloimido bivalirudin, or a combination thereof. The method of using the ready-to-use bivalirudin compositions comprises administering the ready-to-use compositions to a patient in need thereof. Further, the method of preparing the ready-to-use bivalirudin compositions comprises mixing bivalirudin with one or more stabilizing agents.
摘要翻译：即用比伐卢定组合物，使用即用比伐卢定组合物的方法，以及制备即用型比伐卢定组合物的方法。即用型比伐卢列组合物包含比伐卢定和一种或多种稳定剂。一种或多种稳定剂可以是pKa为约2.5至约6.5的缓冲剂，pH调节剂，聚合物，防腐剂，抗氧化剂，糖或多元醇或其组合。即用型比伐卢定组合物还可以包含[9-10] - 环亚氨基比伐卢定，[11-12] - 环亚氨基比伐卢定或其组合。使用即用比伐卢定组合物的方法包括将即用组合物给予有需要的组合物。此外，制备即用型比伐卢定组合物的方法包括将比伐卢定与一种或多种稳定剂混合。

3. 发明授权

US07772274B1 Docetaxel formulations with lipoic acid 有权
标题翻译：多西他赛制剂与硫辛酸
公开(公告)号：US07772274B1
公开(公告)日：2010-08-10
申请号：US12721563
申请日：2010-03-11
申请人： Nagesh Palepu
发明人： Nagesh Palepu
IPC分类号： A61K31/337
CPC分类号： A61K31/337 , A61K9/0019 , A61K47/10 , A61K47/12
摘要： Pharmaceutical formulations comprising docetaxel, solubilizer, and α-lipoic acid, wherein the formulation is substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol, acetic acid, benzyl alcohol, or ethanol. The α-lipoic acid, at certain concentrations, may impart stability and prevent degradation of docetaxel while the formulations are in storage. The formulations may be combined with a diluent, which comprises one or more hydrotropes such as tocopherol polyethylene glycol succinate and polyethylene glycol. The formulations combined with the diluent also exhibit stability after storage. Methods of administering docetaxel comprise preparing the formulation comprising docetaxel, solubilizer, and α-lipoic acid; mixing the formulation with a diluent; diluting the resulting formulation in saline, water for injection, or the like; and then injecting the formulations into patients in need thereof.
摘要翻译：包含多西紫杉醇，增溶剂和α-硫辛酸的药物制剂，其中制剂基本上不含聚山梨醇酯和聚乙氧基化蓖麻油。增溶剂可以包含糖福，乙酸，苄醇或乙醇。某些浓度的α-硫辛酸可以在制剂储存时赋予稳定性并防止多西紫杉醇的降解。制剂可与稀释剂组合，稀释剂包含一种或多种水溶助长剂如生育酚聚乙二醇琥珀酸酯和聚乙二醇。与稀释剂组合的制剂在储存后也表现出稳定性。给予多西紫杉醇的方法包括制备包含多西紫杉醇，增溶剂和α-硫辛酸的制剂; 将制剂与稀释剂混合; 将所得制剂稀释在盐水，注射用水等中; 然后将制剂注射到有需要的患者体内。

4. 发明申请

US20070190085A1 STABLE PHARMACEUTICAL COMPOSITIONS, PROCESSES FOR MAKING THE SAME AND METHODS OF THEIR USE 失效
标题翻译：稳定的药物组合物，制备它们的方法及其使用方法
公开(公告)号：US20070190085A1
公开(公告)日：2007-08-16
申请号：US11743262
申请日：2007-05-02
申请人： Nagesh PALEPU
发明人： Nagesh PALEPU
IPC分类号： A61K31/34 , A61K9/00
CPC分类号： A61K9/0095 , A61K9/08 , A61K31/34 , A61K47/36 , A61K47/38
摘要： The present invention is generally related to alcohol free, liquid ranitidine formulations for oral administration. In particular, the present invention is related to stable, syrup formulations having ranitidine as an active ingredient for oral administration, processes for making the same, and methods of their use. The ranitidine of the present invention is stable in non-polar media or media having a relatively low polarity such that the dielectric constant is less than about 60, and is achieved by using certain saccharides, certain relatively high molecular weight starches, and/or certain celluloses instead of alcohol.
摘要翻译：本发明通常涉及无酒精的用于口服给药的液体雷尼替丁制剂。特别地，本发明涉及具有雷尼替丁作为口服给药的活性成分的稳定的糖浆制剂，其制备方法及其使用方法。本发明的雷尼替丁在具有相对低极性的非极性介质或介质中是稳定的，使得介电常数小于约60，并且通过使用某些糖，某些相对高分子量的淀粉和/或某些纤维素代替酒精。

5. 发明授权

US06864386B1 Fluorinated compounds 失效
标题翻译：氟化合物
公开(公告)号：US06864386B1
公开(公告)日：2005-03-08
申请号：US10300676
申请日：2002-11-20
申请人： Yuehua Zhang , Manjari Lal , Andrew Leo , Nagesh Palepu
发明人： Yuehua Zhang , Manjari Lal , Andrew Leo , Nagesh Palepu
IPC分类号： C07C43/11 , C07C69/40 , C07C271/20 , C07C69/34
CPC分类号： B01F17/0035 , B01F17/005 , C07C43/11 , C07C59/135 , C07C69/40 , C07C271/20 , C07D311/72
摘要： Fluorinated compounds and emulsions including the compounds. The compositions are useful as oxygen carriers and surfactants. In one embodiment, the fluorinated compound is pH sensitive. In one embodiment, the fluorinated compound is a vitamin E derivative. In one embodiment, the fluorinated compound is a vitamin K derivative.
摘要翻译：含氟化合物和包括该化合物的乳液。该组合物可用作氧载体和表面活性剂。在一个实施方案中，氟化化合物是pH敏感的。在一个实施方案中，氟化化合物是维生素E衍生物。在一个实施方案中，氟化化合物是维生素K衍生物。

6. 发明授权

US06300359B1 (E)-3-[1-n-Butyl-5-[2-(2-carboxyphenyl)methoxy-4-chlorophenyl]-1H-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-enoic acid monoargininyl salt 失效
标题翻译：（E）-3- [1-正丁基-5- [2-（2-羧基苯基）甲氧基-4-氯苯基] -1H-吡唑-4-基] -2 - [（5-甲氧基-2,3 - 二氢苯并呋喃-6-基）甲基] - 丙-2-烯酸单炔基盐
公开(公告)号：US06300359B1
公开(公告)日：2001-10-09
申请号：US09581066
申请日：2000-06-08
申请人： Joseph Robert Flisak , Albert Stephen Kearney , Nagesh Palepu , Cherng-Yih Perng
发明人： Joseph Robert Flisak , Albert Stephen Kearney , Nagesh Palepu , Cherng-Yih Perng
IPC分类号： A61K31415
CPC分类号： C07D405/06
摘要： This invention relates to a new monoargininyl salt form of the endothelin receptor antagonist (E)-3-[1-n-Butyl-5-[2-(2-carboxyphenyl)methoxy-4-chlorophenyl]-1H-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-enoic acid.
摘要翻译：本发明涉及内皮素受体拮抗剂（E）-3- [1-正丁基-5- [2-（2-羧基苯基）甲氧基-4-氯苯基] -1H-吡唑-4-酮的新单炔雌醇盐形式吡啶-2-基] -2 - [（5-甲氧基-2,3-二氢苯并呋喃-6-基）甲基] - 丙-2-烯酸。

7. 发明申请

US20110092581A1 Docetaxel Formulations with Lipoic Acid 有权
标题翻译：多西他赛制剂与硫辛酸
公开(公告)号：US20110092581A1
公开(公告)日：2011-04-21
申请号：US12721564
申请日：2010-03-11
申请人： Nagesh Palepu
发明人： Nagesh Palepu
IPC分类号： A61K31/337 , A61P35/00
CPC分类号： A61K31/337 , A61K9/0019 , A61K9/08 , A61K47/10 , A61K47/12 , A61K47/44
摘要： Pharmaceutical formulations comprising docetaxel, solubilizer, and α-lipoic acid, wherein the formulation is substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol, acetic acid, benzyl alcohol, or ethanol. The α-lipoic acid, at certain concentrations, may impart stability and prevent degradation of docetaxel while the formulations are in storage. The formulations may be combined with a diluent, which comprises one or more hydrotropes such as tocopherol polyethylene glycol succinate and polyethylene glycol. The formulations combined with the diluent also exhibit stability after storage. Methods of administering docetaxel comprise preparing the formulation comprising docetaxel, solubilizer, and α-lipoic acid; mixing the formulation with a diluent; diluting the resulting formulation in saline, water for injection, or the like; and then injecting the formulations into patients in need thereof.
摘要翻译：包含多西紫杉醇，增溶剂和α-硫辛酸的药物制剂，其中制剂基本上不含聚山梨醇酯和聚乙氧基化蓖麻油。增溶剂可以包含糖福，乙酸，苄醇或乙醇。某些浓度的α-硫辛酸可以在制剂储存时赋予稳定性并防止多西紫杉醇的降解。制剂可与稀释剂组合，稀释剂包含一种或多种水溶助长剂如生育酚聚乙二醇琥珀酸酯和聚乙二醇。与稀释剂组合的制剂在储存后也表现出稳定性。给予多西紫杉醇的方法包括制备包含多西紫杉醇，增溶剂和α-硫辛酸的制剂; 将制剂与稀释剂混合; 将所得制剂稀释在盐水，注射用水等中; 然后将制剂注射到有需要的患者体内。

8. 发明申请

US20090042774A1 Parathyroid hormone analogues and methods of use 审中-公开
标题翻译：甲状旁腺激素类似物和使用方法
公开(公告)号：US20090042774A1
公开(公告)日：2009-02-12
申请号：US11799816
申请日：2007-05-02
申请人： Paul Morley , Martin Stogniew , Brian MacDonald , Gene Scott Merutka , Nagesh Palepu
发明人： Paul Morley , Martin Stogniew , Brian MacDonald , Gene Scott Merutka , Nagesh Palepu
IPC分类号： A61K38/29 , A61P19/00
CPC分类号： A61K38/29
摘要： The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects.
摘要翻译：本发明涉及用骨缺损障碍治疗受试者的新方法。所述方法通常包括向有需要的受试者施用包含甲状旁腺激素（PTH）肽类似物的药学上可接受的制剂，其日剂量足以导致有效的药代动力学特征并维持腺苷酸环化酶活性，同时减少不期望的副作用。

9. 发明申请

US20060252840A1 Fluorinated compounds 审中-公开
公开(公告)号：US20060252840A1
公开(公告)日：2006-11-09
申请号：US11451727
申请日：2006-06-12
申请人： Yuehua Zhang , Manjari Lal , Andrew Leo , Nagesh Palepu
发明人： Yuehua Zhang , Manjari Lal , Andrew Leo , Nagesh Palepu
IPC分类号： B01F17/00 , C07C229/26 , C07C229/02
CPC分类号： B01F17/0035 , B01F17/005 , C07C43/11 , C07C59/135 , C07C69/40 , C07C271/20 , C07D311/72
摘要： Fluorinated compounds and emulsions including the compounds. The compositions are useful as oxygen carriers and surfactants. In one embodiment, the fluorinated compound is pH sensitive. In one embodiment, the fluorinated compound is a vitamin E derivative. In one embodiment, the fluorinated compound is a vitamin K derivative.

10. 发明授权

US06858227B1 Vitamin E conjugates 失效
标题翻译：维生素E缀合物
公开(公告)号：US06858227B1
公开(公告)日：2005-02-22
申请号：US10300678
申请日：2002-11-20
申请人： Manjari Lal , Yuehua Zhang , Nagesh Palepu
发明人： Manjari Lal , Yuehua Zhang , Nagesh Palepu
IPC分类号： A61K9/08 , A61K9/107 , A61K9/127 , A61K31/4015 , A61K47/18 , A61K47/22 , C07D405/12 , C07D407/12
CPC分类号： C07D405/12 , A61K47/18 , A61K47/22
摘要： Vitamin E conjugates, methods for their preparation, and compositions that include the conjugates. The vitamin E conjugates include a tocopherol moiety covalently coupled through a linker moiety to either a pyroglutamate moiety, a pyrrolidinone moiety, or a gentisic acid moiety.
摘要翻译：维生素E缀合物，其制备方法和包含缀合物的组合物。维生素E缀合物包括通过连接体部分与焦谷氨酸部分，吡咯烷酮部分或龙胆酸部分共价偶联的生育酚部分。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式